Gertjan (GJ) Wolbink MD PhD
'C-Reactive protein mediated activation of complement'
1996 - University of Amsterdam
- Research interests
Pathogenesis and treatment of rheumatoid arthritis
An increasing number of patients beneﬁt from biotherapeuticals. However, some patients do not respond to treatment and others loose their response after a certain time. Immunogenicity is one of the factors linked to secondary nonresponse but its clinical signiﬁcance has remained controversial.In recent years, knowledge of how to assess immunogenicity of biologicals has improved. Various reports show an inverse relationship between drug levels and antibody formation against the drug. Studies associated immunogenicity of therapeutic antibodies with clinically signiﬁcant nonresponse in a subgroup of patients. Clinically relevant immunogenicity is inﬂuenced by several factors including dosing and concomitant medication. Immunogenicity affects a signiﬁcant number of patients treated with biologicals. Monitoring of drug levels as well as of antibodies against therapeutic antibodies may lead to more rational treatment strategies.
2004-present Rheumatologist at the Jan van Breemen Research Institute / Reade and Researcher at Dept of Immunopathology, Sanquin Research 2000-2003 Training as a rheumatologist at the Free University of Amsterdam 1997-2000 Training internal medicine AMC/Slotervaart Hospital Amsterdam 1992-1996 PhD student at the Dept of Pathophysiology of Plasma Proteins at CLB / Sanquin Research 1983-1991 Medicine at the State University Groningen
- Sanquin publications